Results of 5-azacitidine therapy in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML)

被引：0
|
作者：
Freyrie, A. [1 ]
Reda, G. [1 ]
Vincenti, D. [1 ]
Ferla, V. [1 ]
Orofino, N. [1 ]
Sciume, M. [1 ]
Guidotti, F. [1 ]
Cortelezzi, A. [1 ]
机构：
[1] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Hematol & Transplantat Unit, Milan, Italy
来源：
LEUKEMIA RESEARCH | 2013年 / 37卷
关键词：
D O I：
10.1016/S0145-2126(13)70348-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-301
引用
收藏
页码：S157 / S158
页数：2
相关论文
共 50 条
  • [1] 5-Azacitidine Therapy in Patients with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia: a Single Institution Experience
    Freyrie, Alessandra
    Reda, Gianluigi
    Vincenti, Daniele
    Sciume, Mariarita
    Binda, Francesca
    Guidotti, Francesca
    Cortelezzi, Agostino
    [J]. BLOOD, 2012, 120 (21)
  • [2] Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML)
    Kenealy, Melita
    Patton, Nigel
    Filshie, Robin
    Nicol, Andrew
    Ho, Shir-Jing
    Hertzberg, Mark
    Mills, Tony
    Prosser, Ian
    Link, Emma
    Cowan, Linda
    Zannino, Diana
    Seymour, John F.
    [J]. LEUKEMIA & LYMPHOMA, 2017, 58 (02) : 298 - 307
  • [3] Possible Biomarkers To Predict Response In Patients With Myelodysplastic Syndromes (MDS) Or Acute Myeloid Leukemia (AML) Treated With 5-Azacitidine
    Kuendgen, Andrea
    Mueller-Thomas, Catharina
    Urbaniak, Petra
    Lauseker, Michael
    Haferlach, Torsten
    Alpermann, Tamara
    Albuquerque, Andreia
    Kohlmann, Alexander
    Schnittger, Susanne
    Hildebrandt, Barbara
    Royer-Pokora, Brigitte
    Gattermann, Norbert
    Haas, Rainer
    Germing, Ulrich
    Goetze, Katharina
    [J]. BLOOD, 2013, 122 (21)
  • [4] EXTENDED CC-486 (ORAL AZACITIDINE) DOSING IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS), ACUTE MYELOID LEUKEMIA (AML), OR CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): SAFETY, TOLERABILITY, AND RESPONSE
    Savona, M. R.
    Kolibaba, K.
    Conkling, P.
    Kingsley, E. C.
    Becerra, C.
    Morris, J. C.
    Rifkin, R. M.
    Laille, E.
    Kellerman, A.
    Ukrainskyj, S. M.
    Dong, Q.
    Skikne, B. S.
    [J]. LEUKEMIA RESEARCH, 2015, 39 : S29 - S30
  • [5] Determination of a Phase II Dose of Panobinostat in Combination with 5-Azacitidine in Patients with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
    Ottmann, Oliver G.
    DeAngelo, Daniel J.
    Garcia-Manero, Guillermo
    Luebbert, Michael
    Jillella, Anand
    Sekeres, Mikkael A.
    Zahlten, Anita
    Squier, Margaret
    Acharyya, Suddhasatta
    Winiger, Ivo J.
    Fenaux, Pierre
    [J]. BLOOD, 2011, 118 (21) : 212 - 213
  • [6] Phase 1 study of LP-108 as monotherapy and in combination with azacitidine in patients with relapsed or refractory myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML).
    Walker, Alison R.
    Bergua Burgues, Juan Miguel
    Montesinos, Pau
    Bixby, Dale
    Guastad Daver, Naval
    Konopleva, Marina
    Patrick Anthony, Stephen
    Tan, Fenlai
    Chen, Yi
    Chen, Yu
    Shen, Yue
    William Burke, Patrick
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] SINGLE INSTITUTION EXPERIENCE OF 5-AZACITIDINE THERAPY IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA
    Freyrie, A.
    Guidotti, F.
    Reda, G.
    Binda, F.
    Cortelezzi, A.
    [J]. HAEMATOLOGICA, 2012, 97 : 587 - 587
  • [8] Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)
    Steensma, David P.
    Wermke, Martin
    Klimek, Virginia M.
    Greenberg, Peter L.
    Font, Patricia
    Komrokji, Rami S.
    Yang, Jay
    Brunner, Andrew M.
    Carraway, Hetty E.
    Ades, Lionel
    Al-Kali, Aref
    Dominguez, Juan Manuel Alonso
    Alonso, Ana
    Coombs, Catherine C.
    Deeg, H. Joachim
    Donnellan, William B.
    Foran, James M.
    Garcia-Manero, Guillermo
    Maris, Michael B.
    McMasters, Malgorzata
    Micol, Jean-Baptiste
    De Oteyza, Jaime Perez
    Thol, Felicitas
    Wang, Eunice S.
    Watts, Justin M.
    Buonamici, Silvia
    Kim, Amy
    Gourineni, Vikram
    Marino, Alyssa J.
    Rioux, Nathalie
    Schindler, Joanne
    Smith, Sherri
    Yao, Huilan
    Yuan, Xiaobin
    Yu, Kun
    Platzbecker, Uwe
    [J]. BLOOD, 2019, 134
  • [9] Azacitidine access program for Belgian patients with myelodysplastic syndromes, acute myeloid leukemia or chronic myelomonocytic leukemia
    Meers, S.
    Selleslag, D.
    Potier, H.
    Glasmacher, A.
    Mineur, P.
    Voelter, V.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2015, 31 (01) : 35 - 42
  • [10] IMPACT OF BONE MARROW FIBROSIS IN RESPONSE TO AZACITIDINE IN 94 PATIENTS WITH MYELODISPLASTIC SYNDROMES (MDS), CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) AND ACUTE MYELOID LEUKEMIA
    Reda, G.
    Riva, M.
    Cassin, R.
    Fattizzo, B.
    Deodato, M.
    Freyrie, A.
    Molteni, A.
    Cairoli, R.
    Cortelezzi, A.
    [J]. HAEMATOLOGICA, 2016, 101 : 241 - 242
12345